Effects of antiviral agents and HBV genotypes on intrahepatic covalently closed circular DNA in HBeA

[Guest guest]

World J Gastroenterol. 2008 Feb 28;14(8):1268-73.

Effects of antiviral agents and HBV genotypes on intrahepatic covalently closed

circular DNA in HBeAg-positive chronic hepatitis B patients.

Lu HY, Zhuang LW, Yu YY, Si CW, Li J, Zhang JJ, Zeng Z, Chen XY, Han ZH, Chen Y.

Department of Infectious Diseases, Peking University First Hospital, Beijing

100034, China. yyy@....

AIM: To evaluate the effects of antiviral agents and HBV genotypes on

intrahepatic covalently closed circular DNA (ccc DNA) in HBeAg-positive chronic

hepatitis B patients. METHODS: Seventy-one patients received lamivudine (n =

35), or sequential therapy with lamivudine- interferon alpha 2b (IFN-alpha 2b, n

= 24) for 48 wk, or IFN-alpha 2b (n = 12) for 24 wk. All subjects were followed

up for 24 wk. Intrahepatic ccc DNA was measured quantitatively by PCR. HBV

genotypes were analyzed by PCR-RFLP. RESULTS: Sequential lamivudine- INF-alpha

therapy, lamivudine and INF-alpha monotherapy reduced ccc DNA of 1.7 log, 1.4

log and 0.8 log, respectively (P < 0.05). Seventeen out of the 71 patients

developed HBeAg seroconversion, the reduction of ccc DNA in the HBeAg

seroconversion patients was more significant than that in the HBeAg positive

patients (3.0 log vs 1.6 log, P = 0.0407). Twenty-four weeks after antiviral

therapy withdrawal, 16 patients had a sustained virological response, the

baseline intrahepatic ccc DNA in the patients with a sustained virological

response was significantly lower than that in the patients with virological

rebound (4.6 log vs 5.4 log, P = 0.0472). HBV genotype C accounted for 85.9% (n

= 61), and genotype B for 14.1% (n = 10), respectively, in the 71 patients.

There was no significant difference in the change of ccc DNA level between HBV

genotypes C and B (2.1 log vs 1.9 log). CONCLUSION: Forty-eight week sequential

lamivudine-INF-alpha therapy and lamivudine monotherapy reduce ccc DNA more

significantly than 24-wk INF-alpha monotherapy. Low baseline intrahepatic ccc

DNA level may predict the long-term efficacy of antiviral treatment. HBV

genotypes C and B have no obvious influence on ccc DNA load.

PMID: 18300356 [PubMed - in process]

_________________________________________________________________

Shed those extra pounds with MSN and The Biggest Loser!

http://biggestloser.msn.com/

[Guest guest]

World J Gastroenterol. 2008 Feb 28;14(8):1268-73.

Effects of antiviral agents and HBV genotypes on intrahepatic covalently closed

circular DNA in HBeAg-positive chronic hepatitis B patients.

Lu HY, Zhuang LW, Yu YY, Si CW, Li J, Zhang JJ, Zeng Z, Chen XY, Han ZH, Chen Y.

Department of Infectious Diseases, Peking University First Hospital, Beijing

100034, China. yyy@....

AIM: To evaluate the effects of antiviral agents and HBV genotypes on

intrahepatic covalently closed circular DNA (ccc DNA) in HBeAg-positive chronic

hepatitis B patients. METHODS: Seventy-one patients received lamivudine (n =

35), or sequential therapy with lamivudine- interferon alpha 2b (IFN-alpha 2b, n

= 24) for 48 wk, or IFN-alpha 2b (n = 12) for 24 wk. All subjects were followed

up for 24 wk. Intrahepatic ccc DNA was measured quantitatively by PCR. HBV

genotypes were analyzed by PCR-RFLP. RESULTS: Sequential lamivudine- INF-alpha

therapy, lamivudine and INF-alpha monotherapy reduced ccc DNA of 1.7 log, 1.4

log and 0.8 log, respectively (P < 0.05). Seventeen out of the 71 patients

developed HBeAg seroconversion, the reduction of ccc DNA in the HBeAg

seroconversion patients was more significant than that in the HBeAg positive

patients (3.0 log vs 1.6 log, P = 0.0407). Twenty-four weeks after antiviral

therapy withdrawal, 16 patients had a sustained virological response, the

baseline intrahepatic ccc DNA in the patients with a sustained virological

response was significantly lower than that in the patients with virological

rebound (4.6 log vs 5.4 log, P = 0.0472). HBV genotype C accounted for 85.9% (n

= 61), and genotype B for 14.1% (n = 10), respectively, in the 71 patients.

There was no significant difference in the change of ccc DNA level between HBV

genotypes C and B (2.1 log vs 1.9 log). CONCLUSION: Forty-eight week sequential

lamivudine-INF-alpha therapy and lamivudine monotherapy reduce ccc DNA more

significantly than 24-wk INF-alpha monotherapy. Low baseline intrahepatic ccc

DNA level may predict the long-term efficacy of antiviral treatment. HBV

genotypes C and B have no obvious influence on ccc DNA load.

PMID: 18300356 [PubMed - in process]

_________________________________________________________________

Shed those extra pounds with MSN and The Biggest Loser!

http://biggestloser.msn.com/